propranolol has been researched along with Cavernous Angioma, Central Nervous System in 16 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this case, we describe an evident hemorrhagic brainstem cavernous malformation successfully treated with a planned sequence of surgical evacuation of the hematoma followed by postoperative propranolol therapy." | 7.96 | Successful treatment of hemorrhagic brainstem cavernous malformation with hematoma evacuation and postoperative propranolol. ( Armstrong, J; Greenan, K; Hoffman, JE; Ryan, M; Wilkinson, C; Wittenberg, B, 2020) |
| "In this case, we describe an evident hemorrhagic brainstem cavernous malformation successfully treated with a planned sequence of surgical evacuation of the hematoma followed by postoperative propranolol therapy." | 3.96 | Successful treatment of hemorrhagic brainstem cavernous malformation with hematoma evacuation and postoperative propranolol. ( Armstrong, J; Greenan, K; Hoffman, JE; Ryan, M; Wilkinson, C; Wittenberg, B, 2020) |
| "Propranolol was safe and well tolerated in this population." | 3.30 | Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial. ( Al-Shahi Salman, R; Bertani, GA; Dejana, E; Lanfranconi, S; Latini, R; Meessen, JMTA; Pallini, R; Scola, E, 2023) |
| "Propranolol has recently been shown to be effective in the treatment of infantile hemangioma, a close pathologic counterpart of cavernous malformations." | 1.43 | Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. ( Filippidis, AS; Kalani, MYS; Spetzler, RF; Zabramski, JM, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 8 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shenkar, R | 2 |
| Moore, T | 2 |
| Benavides, C | 2 |
| Lightle, R | 2 |
| Detter, MR | 2 |
| Hobson, N | 2 |
| Girard, R | 2 |
| DeBiasse, D | 1 |
| Patrucco, M | 1 |
| Gallione, C | 2 |
| Zabramski, JM | 5 |
| Marchuk, DA | 2 |
| Awad, IA | 2 |
| Tiefenbach, J | 1 |
| Park, JJ | 1 |
| Kaliaperumal, C | 1 |
| Lanfranconi, S | 4 |
| Scola, E | 4 |
| Meessen, JMTA | 4 |
| Pallini, R | 4 |
| Bertani, GA | 4 |
| Al-Shahi Salman, R | 4 |
| Dejana, E | 5 |
| Latini, R | 4 |
| Hoffman, JE | 1 |
| Ryan, M | 1 |
| Wittenberg, B | 1 |
| Armstrong, J | 1 |
| Greenan, K | 1 |
| Wilkinson, C | 1 |
| Zarino, B | 1 |
| d'Alessandris, G | 1 |
| Mazzon, E | 1 |
| Marino, S | 1 |
| Carriero, MR | 1 |
| Scelzo, E | 1 |
| Faragò, G | 1 |
| Castori, M | 1 |
| Fusco, C | 1 |
| Petracca, A | 1 |
| d'Agruma, L | 1 |
| Tassi, L | 1 |
| d'Orio, P | 1 |
| Lampugnani, MG | 2 |
| Nicolis, EB | 1 |
| Vasamì, A | 1 |
| Novelli, D | 1 |
| Torri, V | 1 |
| Li, W | 1 |
| Cao, Y | 1 |
| Li, Y | 1 |
| Griffin, E | 1 |
| Ginsberg, MH | 1 |
| Oldenburg, J | 1 |
| Malinverno, M | 1 |
| Globisch, MA | 1 |
| Maderna, C | 1 |
| Corada, M | 1 |
| Orsenigo, F | 1 |
| Conze, LL | 1 |
| Rorsman, C | 1 |
| Sundell, V | 1 |
| Arce, M | 1 |
| Smith, RO | 1 |
| Yau, ACY | 1 |
| Billström, GH | 1 |
| Mägi, CÖ | 1 |
| Beznoussenko, GV | 1 |
| Mironov, AA | 1 |
| Fernando, D | 1 |
| Daniel, G | 1 |
| Olivari, D | 1 |
| Fumagalli, F | 1 |
| Magnusson, PU | 1 |
| Apra, C | 1 |
| Dumot, C | 1 |
| Bourdillon, P | 1 |
| Pelissou-Guyotat, I | 1 |
| Berti, I | 1 |
| Marchetti, F | 1 |
| Skabar, A | 1 |
| Zennaro, F | 1 |
| Zanon, D | 1 |
| Ventura, A | 1 |
| Miquel, J | 1 |
| Bruneau, B | 1 |
| Dupuy, A | 1 |
| Kalani, MYS | 1 |
| Filippidis, AS | 2 |
| Spetzler, RF | 2 |
| Reinhard, M | 1 |
| Schuchardt, F | 1 |
| Meckel, S | 1 |
| Heinz, J | 1 |
| Felbor, U | 1 |
| Sure, U | 1 |
| Geisen, U | 1 |
| Moschovi, M | 1 |
| Alexiou, GA | 1 |
| Stefanaki, K | 1 |
| Tourkantoni, N | 1 |
| Prodromou, N | 1 |
| Fountas, KN | 1 |
| Kalani, MY | 1 |
| Ghosh, PS | 1 |
| Ghosh, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treat_CCM Clinical Trial A Multicenter Randomized Clinical Trial on Propranolol in Familial Cerebral Cavernous Malformation[NCT03589014] | Phase 2 | 71 participants (Actual) | Interventional | 2018-04-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for propranolol and Cavernous Angioma, Central Nervous System
| Article | Year |
|---|---|
A 5-year outcome of propranolol for the treatment of paediatric intracranial cavernoma: case report and a review of the literature.
Topics: Child; Hemangioma, Cavernous, Central Nervous System; Humans; Intracranial Hemorrhages; Magnetic Res | 2023 |
Could propranolol be beneficial in adult cerebral cavernous malformations?
Topics: Adrenergic beta-Antagonists; Brain Neoplasms; Cardiovascular Agents; Hemangioma, Cavernous, Central | 2019 |
2 trials available for propranolol and Cavernous Angioma, Central Nervous System
12 other studies available for propranolol and Cavernous Angioma, Central Nervous System
| Article | Year |
|---|---|
Propranolol as therapy for cerebral cavernous malformations: a cautionary note.
Topics: Brain Neoplasms; Hemangioma, Cavernous, Central Nervous System; Humans; Magnetic Resonance Imaging; | 2022 |
Successful treatment of hemorrhagic brainstem cavernous malformation with hematoma evacuation and postoperative propranolol.
Topics: Child, Preschool; Hemangioma, Cavernous; Hemangioma, Cavernous, Central Nervous System; Hematoma; Hu | 2020 |
Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Apoptosis Regulatory Proteins; Female; G-Protein-Co | 2021 |
In Reply to the Letter to the Editor Regarding "Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage".
Topics: Hemangioma, Cavernous, Central Nervous System; Hemorrhage; Humans; Propranolol | 2021 |
Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations: A Preclinical Study.
Topics: Animals; Central Nervous System Neoplasms; Disease Models, Animal; Female; Hemangioma, Cavernous, Ce | 2021 |
Propranolol for cerebral cavernous angiomatosis: a magic bullet.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Brain Neoplasms; Female; Hemangioma, Cavernous, | 2014 |
Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol.
Topics: Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; | 2014 |
Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage.
Topics: Adrenergic beta-Antagonists; Adult; Brain Neoplasms; Cerebral Hemorrhage; Female; Hemangioma, Cavern | 2016 |
Propranolol stops progressive multiple cerebral cavernoma in an adult patient.
Topics: Brain; Disease Progression; Follow-Up Studies; Hemangioma, Cavernous, Central Nervous System; Humans | 2016 |
Propranolol treatment for a giant infantile brain cavernoma.
Topics: Antigens, CD34; Antineoplastic Agents; Blood Vessels; Brain; Brain Neoplasms; Hemangioma, Cavernous, | 2010 |
Letter by Filippidis et al regarding article, "Evaluating strategies for the treatment of cerebral cavernous malformations".
Topics: Adrenergic Antagonists; Central Nervous System Neoplasms; Central Nervous System Vascular Malformati | 2011 |
Infantile intraspinal and extensive cutaneous hemangiomas: excellent response to propranolol.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Female; Hemangioma; Hemangioma, Cavernous, Cen | 2011 |